Why You Can’t Ban a Molecule: North Carolina’s Cannabis Debate Meets Chemistry

North Carolina is not a major cannabis market in the way California or New York are. It has no adult-use program and no functioning medical system. But it has something else: a fast-growing, largely unregulated market for cannabis products that exists in the gap between federal hemp law and state prohibition. The result is a hybrid system where illegal marijuana and legal hemp-derived products are sold side by side, often with few meaningful controls.

State officials now acknowledge that this structure is unstable. A recent interim report from the North Carolina Department of Health and Human Services’ Advisory Council on Cannabis describes the current environment as a “dangerous policy gap” marked by inconsistent testing, mislabeled potency, contamination risks, and widespread availability of high-THC products. Governor Josh Stein has called the market a “Wild West,” pushing lawmakers toward a regulated system that imposes standards on a market that already exists rather than attempting to eliminate it.

At the same time, opposition voices argue that the solution is not legalization but enforcement — closing loopholes and restoring prohibition. That debate is now intersecting with a more technical framing highlighted in a recent Policy, Decoded edition: the shift from regulating cannabis by plant to regulating it by molecule.

Where Policy Meets Reality

The core assumption behind prohibition is simple: restrict supply, and use will decline.

But markets do not behave that way.

People are not tied to a specific compound. When one product is restricted, alternatives emerge. That has already happened in cannabis, where shifts in regulation have been followed by the rise of new cannabinoids and reformulated products.

North Carolina’s own report points to another issue. Even limited systems can create access barriers.

“A medical-only cannabis market can create meaningful access barriers for some patients, particularly those in rural areas, individuals with limited transportation, lower-income patients, older adults, and those undergoing intensive treatment, for whom additional appointments, certifications, and travel requirements may make access to products more difficult.”

When access is restricted, demand does not disappear. It moves. And when it moves, it often shifts into markets with fewer safeguards.

The Limits of Prohibiting a Molecule

1. The molecule is not fixed

Delta-9 THC is only one version of a broader class of compounds. Small structural changes produce isomers like delta-8 and delta-10, which can generate similar effects. When regulation targets one molecule, the market shifts to another with minimal functional difference. Regulating overall cannabinoid content and product characteristics is more durable than targeting individual compounds.

2. Chemical conversion sustains supply

Many products are created through chemical conversion, often starting from hemp-derived CBD. This allows producers to generate new compounds even when specific outputs are restricted. The advisory council highlights risks tied to these processes, including contamination and inconsistent formulation. Regulating manufacturing methods, inputs, and testing standards addresses these risks more directly than banning end products.

3. The body responds to effects, not labels

The human endocannabinoid system responds to receptor activity, not legal definitions. A range of compounds can interact with the same biological pathways. From a behavioral standpoint, consumers seek outcomes, not compliance with a statutory definition. Regulations that focus on dosing and safety align more closely with real-world use.

4. Innovation outpaces enforcement

New compounds can be developed faster than laws can be updated. This pattern is well established in broader chemical markets. Regulations that depend on identifying and banning individual molecules will always lag behind production. Systems that focus on standards, monitoring, and compliance are better positioned to keep up.

5. Bans increase risk through substitution

When familiar compounds are restricted, they are often replaced with less-studied alternatives. This increases uncertainty around quality and safety. Setting clear rules around testing, labeling, and allowable product standards reduces risk more effectively than attempting to eliminate entire categories.

The Real Choice

North Carolina is right that its current system is neither a meaningful prohibition nor a meaningful regulation. The next step is not to redraw the line at the molecular level and assume the problem is solved.

A system built on prohibition assumes that supply can be eliminated. A system built on regulation assumes that demand will persist. Only one of those assumptions is consistent with both economics and chemistry.

And it is not a prohibition.

A more durable approach is structural. It recognizes that public health depends on market health — on transparent supply chains, enforceable standards, and accountable participants. Well-designed regulation can reduce risk, improve product quality, and generate tax revenue that supports communities, healthcare systems, and local economies.

The question is no longer whether cannabis exists in North Carolina. The question is whether policy will be built to manage that reality, or continue trying to outpace it.